ALL-in-1
ActiveSummary
ALL-in-1 has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €109,086 and a net result of -€66,054. Equity has been growing by about 34% per year since 2019. Its solvency ranks better than 9% of 6,172 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 1.2% (low).
Overview
Official details
Source: KBO- Status
- Active since 08-04-2004 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460and 2 others
- Joint committees
- 116 Paritair Comité voor de scheikundige nijverheid
- 200 Aanvullend Paritair Comité voor de bedienden
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 30-06-2024
- Establishment unit
- 2.175.712.077 2627 Schelle, since 20-01-2009
- Financial year end
- 30 June
- Peppol
- Reachable since 22-10-2025
Board and ownership
- INPHAGRO BVDirector · since 29-05-2018
- LBS BVDirector · since 04-02-2021
- INPHAGRO100%30-06-2025 annual accounts of INPHAGRO
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.2%
- Turnover
- €26.3m
- ▼ 24.7%
- Loss
- €66,054
- Equity
- €109,086
- ▼ 37.7%
- Total assets
- €9.0m
- ▼ 20.4%
- Employees on 30-06-2025
- 20
- ▲ 5.3%
Score breakdownraises riskLiquidity: current ratio 0.97, cash €396,971Equity €109,086 (1.2% of total assets)2 of the last 3 accounts latelowers riskFounded in 2004Show the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 5% of them on solvency, 5% on liquidity, 25% on profitability and 6% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 21 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Resignation: Baker Tilly Bedrijfsrevisoren BV (statutory auditor)Reappointment: Baker Tilly Bedrijfsrevisoren BV (statutory auditor) · Permanent representative: Sean Mc Cullough
- · Gazette deed Resignations & appointmentsReappointment: Caluwaerts & Co Bedrijfsrevisoren BV (statutory auditor) · Permanent representatives: Christian Caluwaerts and Lode Asselman · Appointment: Baker Tilly Bedrijfsrevisoren BV (statutory auditor)
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as ALL-in-1: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €7.1m and €14m, founded between 1992 and 2008.
| Company | Total assets | Turnover |
|---|---|---|
| ALL-in-1 Schelle | €9.0m | €26.3m |
| NOBEL BIOCARE BELGIUM Mechelen | €14.0m | €25.9m |
| THERMO FISHER DIAGNOSTICS Merelbeke-Melle | €12.0m | €23.6m |
| STRAUMANN Zaventem | €10.5m | €27.9m |
| INNOMEDIQ Heist-op-den-Berg | €12.3m | €15.3m |
| EMDOKA Hoogstraten | €9.5m | €17.3m |
| ALEAMED Kontich | €7.1m | €15.9m |
Key facts about ALL-in-1
- What is the company number of ALL-in-1?
- The company number of ALL-in-1 is 0864.603.461. The VAT number is the same number with BE in front: BE 0864.603.461.
- Where is ALL-in-1 based?
- The registered office is at Molenberglei 36, 2627 Schelle.Company details
- What does ALL-in-1 do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of ALL-in-1?
- The legal form of ALL-in-1 is Private limited company (BV).
- When was ALL-in-1 founded?
- ALL-in-1 was founded on 08-04-2004.
- Is ALL-in-1 still active?
- Yes, ALL-in-1 is an active enterprise in the KBO register.
- How many employees does ALL-in-1 have?
- ALL-in-1 had an average of 18.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ALL-in-1 fall under?
- In its 30-06-2024 annual accounts, ALL-in-1 states joint committees 116 (Paritair Comité voor de scheikundige nijverheid), 200 (Aanvullend Paritair Comité voor de bedienden) and 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of ALL-in-1?
- The turnover of ALL-in-1 was €26.3m in financial year 2025, according to the filed annual accounts.
- Is ALL-in-1 profitable?
- In financial year 2025, ALL-in-1 made a loss of €66,054.
- Where can I find the annual accounts of ALL-in-1?
- ALL-in-1 filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ALL-in-1 due?
- ALL-in-1 must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.